Kyowa Kirin Co., Ltd. (Tokyo Stock Exchange: 4151), through its subsidiary Kyowa Kirin International plc, has reported final results from the German MINT observational study showing a 62.4% best overall response rate and median time to next treatment of 14.9 months with Poteligeo (mogamulizumab) in patients with mycosis fungoides and Sézary syndrome. The findings, announced on October 11, 2026, following their presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group Annual Meeting in Berlin, provide additional real-world evidence for an established treatment in two rare forms of cutaneous T-cell lymphoma.
The final analysis included 109 patients treated across 18 German specialist centres, with a median follow-up of 25.2 months. Investigators reported median progression-free survival of 20.2 months and improvements in recorded quality-of-life scores, although grade 3 or higher treatment-related adverse events occurred in 38.5% of participants. The results therefore provide information about both treatment outcomes and the toxicity burden encountered in routine clinical practice.
MINT was designed to evaluate how mogamulizumab performs outside a controlled randomized trial, where patients may receive additional therapies and differ considerably in disease stage, clinical characteristics and prior treatment experience. Approximately 83.5% of participants had advanced disease, defined as stage IIB or higher, making the findings relevant to clinicians managing complex cutaneous T-cell lymphoma cases. However, the study did not include an untreated or active-treatment control group, so its response and survival outcomes cannot establish superiority over other treatment strategies.
The analysis also has commercial relevance for Kyowa Kirin, which markets mogamulizumab internationally as a CCR4-directed antibody for adults with previously treated mycosis fungoides or Sézary syndrome. Poteligeo has been authorized in the United States and European Union since 2018, making the latest development an evidence-strengthening milestone rather than a new regulatory approval. Its implications concern treatment sequencing, physician confidence and the medicine’s positioning within an increasingly individualized rare lymphoma treatment landscape.
What does the 14.9-month time to next treatment reveal about Poteligeo’s real-world durability?
The primary endpoint of MINT was time to next treatment, or TTNT, which measures the interval from starting mogamulizumab until a subsequent qualifying therapy is initiated after discontinuation. Unlike progression-free survival, TTNT reflects a treatment pathway influenced by both clinical outcomes and prescribing decisions. It can provide information about how long patients remain without needing another systemic treatment strategy, but it does not exclusively measure the biological activity of the medicine.
Investigators reported a median TTNT of 14.9 months, with a 95% confidence interval of 11.2 to 21.5 months. Outcomes differed between disease subtypes, with a median of 12.0 months among patients with mycosis fungoides and 20.2 months among those with Sézary syndrome. These figures suggest differences in treatment trajectories, although the observational design does not establish that mogamulizumab is inherently more effective in one disease subtype based on TTNT alone.
The distinction matters because decisions to change treatment can depend on disease progression, treatment tolerance, available alternatives and physician preferences. The study’s TTNT definition also excluded certain localized interventions, including topical steroids and focal radiotherapy, from qualifying as the next treatment. Consequently, the endpoint does not mean that every patient remained continuously free from additional therapeutic intervention.
Progression-free survival provides a complementary assessment. MINT reported median progression-free survival of 20.2 months, with a 95% confidence interval extending from 13.3 to 41.0 months. The difference between the TTNT and progression-free survival estimates reflects their distinct definitions and analytical methods, rather than proving that patients experienced uninterrupted disease control for either duration.
Why should MINT’s 62.4% response rate not be directly compared with the MAVORIC Phase 3 trial?
The final MINT analysis reported a best overall response rate of 62.4%, with a 95% confidence interval of 52.6% to 71.5%. The outcome represents patients achieving a documented global complete or partial response during the observational study. It supports evidence of clinical activity in routine care, but the absence of a randomized comparator limits conclusions about how much of the observed response is attributable specifically to mogamulizumab.
The pivotal Phase 3 MAVORIC study previously established mogamulizumab’s efficacy against vorinostat in patients with previously treated mycosis fungoides or Sézary syndrome. In that randomized trial, mogamulizumab achieved a 28% confirmed overall response rate compared with approximately 5% for vorinostat. Median progression-free survival was 7.7 months with mogamulizumab and 3.1 months with vorinostat, demonstrating a statistically significant difference in the prespecified comparison.
The substantially higher response and progression-free survival figures reported in MINT should not be interpreted as evidence that mogamulizumab has become more effective outside clinical trials. The populations, assessment methods, treatment patterns and follow-up procedures differ, and a real-world study can capture treatment outcomes under conditions not permitted or standardized in a randomized investigation.
One particularly important factor is the use of concurrent antineoplastic therapy. MINT reported that 63 of 109 participants, approximately 57.8%, received additional antineoplastic treatments during their course of care. These included extracorporeal photopheresis in 21.1% of patients, total skin electron beam therapy in 8.3%, and other radiotherapy in another 8.3%.
The exploratory best overall response rate was 60.9% among the 46 patients classified in the monotherapy group and 63.5% among the 63 receiving combination treatment. Although the figures are numerically close, the groups were not randomized to different treatment strategies. Differences in disease severity, clinical decision-making and treatment histories could influence the results, preventing a conclusion that combining therapies provides an equivalent or superior outcome.
MINT therefore strengthens understanding of how mogamulizumab is used in complex treatment settings. It does not replace the controlled efficacy evidence established by MAVORIC or justify a direct comparison between the two studies’ headline response percentages.
What do the results show in folliculotropic mycosis fungoides and large cell transformation?
The MINT investigators also evaluated treatment responses in clinically important subgroups that can present additional management challenges. Among 11 patients with large cell transformation, the reported best overall response rate was 54.5%, with a wide 95% confidence interval of 23.4% to 83.3%. In 12 patients with folliculotropic mycosis fungoides, the response rate was 50.0%, with a confidence interval of 21.1% to 78.9%.
These results provide descriptive evidence that responses occurred in both subgroups during routine clinical use. However, the small sample sizes mean the estimates are imprecise, and a limited number of individual outcomes could materially change the reported percentages. The exploratory analyses also do not demonstrate that mogamulizumab performs better than other therapies in either subgroup.
Disease stage was examined separately. Kyowa Kirin reported a best overall response rate of 50.0% among 18 patients with early-stage disease and 64.8% among 91 patients with advanced disease. The higher numerical response in the advanced group should not be interpreted as proof that later-stage patients are more likely to benefit, because treatment histories and disease characteristics may differ substantially.
An additional observation concerns mogamulizumab-associated rash, which occurred in 42.2% of all MINT participants. The conference findings described higher response rates among patients who developed this treatment-associated skin reaction, including exploratory differences within the mycosis fungoides and Sézary syndrome populations. In patients with Sézary syndrome, reported response rates were 96.3% among those with rash and 61.5% among those without it.
This association is clinically interesting but requires particularly cautious interpretation. Patients who remain on treatment longer may have more opportunities both to develop a rash and to demonstrate a response, creating potential confounding. The observational data do not establish that rash causes a favorable treatment outcome or that it is a validated predictive biomarker of efficacy.
Rash can also complicate assessment because drug-related eruptions may resemble the underlying skin manifestations of cutaneous T-cell lymphoma. Distinguishing a treatment reaction from persistent or progressive lymphoma is important for evaluating disease status and making subsequent clinical decisions. The MINT findings reinforce the need to interpret this adverse event in its complete clinical context.
What do the grade 3 adverse events and treatment discontinuations reveal about mogamulizumab safety?
Safety remains a substantial consideration in the final MINT findings. Investigators reported grade 3 or higher treatment-related treatment-emergent adverse events in 38.5% of patients. The most frequently reported severe treatment-related events were drug eruptions, affecting 18.3%, and lymphopenia, affecting 11.9%.
The conference abstract additionally reported serious treatment-emergent adverse events leading to discontinuation in 22.0% of participants. Drug eruption was the most frequently identified event in this category, affecting 6.4% of patients. These outcomes demonstrate that clinically consequential toxicity occurred during treatment, even though the investigators considered the overall safety experience broadly consistent with the established mogamulizumab profile.
The abstract also recorded five patient deaths as treatment-emergent events. It did not establish that all five deaths were caused by mogamulizumab, making it inappropriate to describe them as confirmed treatment-related fatalities. A more complete safety analysis would need to examine event timing, causes of death, disease progression, concurrent conditions and investigators’ assessments of relatedness.
The medicine’s established safety precautions provide important context. United States prescribing information identifies risks including severe dermatologic reactions, infusion-related reactions, serious infections and autoimmune complications. Post-treatment allogeneic hematopoietic stem cell transplantation also carries an increased risk of serious complications, including severe graft-versus-host disease and transplant-related mortality.
These risks are particularly relevant in advanced cutaneous T-cell lymphoma because patients may already have immune dysfunction, extensive skin disease and previous exposure to systemic treatments. A real-world population can provide information about adverse events encountered in more varied clinical circumstances than a controlled trial. Nevertheless, the MINT dataset is not sufficiently large to establish the frequency of every uncommon or delayed complication.
The final study therefore supports the usefulness of continued real-world safety surveillance while confirming that adverse events can meaningfully influence treatment persistence. Its findings should not be summarized simply as showing that mogamulizumab is well tolerated, because a substantial proportion of patients experienced severe treatment-related events.
How meaningful are the reported quality-of-life improvements for patients with rare skin lymphomas?
Quality of life is an especially important outcome in mycosis fungoides and Sézary syndrome because the diseases can produce persistent itching, visible skin lesions, discomfort and sleep disruption. These symptoms may affect social activities, emotional well-being and daily functioning even when conventional disease measurements remain relatively stable. MINT included the Skindex-29 questionnaire to capture aspects of the patient experience.
Kyowa Kirin reported that median Skindex-29 scores decreased from 49.1 at treatment initiation to 30.2 at month 12, representing a 38.5% numerical reduction. Lower scores generally indicate a lower burden of skin-related symptoms and associated quality-of-life impairment. The observation is encouraging, but the available patient numbers place important limits on interpretation.
The company disclosed a baseline sample of 21 patients and a month-12 sample of only seven patients for the reported median values. Because the measurements were obtained from substantially different numbers of participants, the reduction should not automatically be treated as a paired improvement demonstrated across the entire MINT population. Missing observations, treatment discontinuation and differences between patients contributing data at each time point may influence the comparison.
Separate real-world evidence from Kyowa Kirin’s PROSPER study has also examined patient-reported outcomes during mogamulizumab treatment. Findings presented in 2026 described improvements in skin symptoms and health-related quality of life over a 48-week observation period. These results provide additional context for the potential patient experience associated with treatment, although PROSPER and MINT remain distinct observational investigations.
The most useful future assessments would combine standardized clinical disease measurements with sufficiently complete patient-reported outcomes. Such evidence could help determine whether documented lymphoma responses are accompanied by improvements that patients experience in everyday life. The current MINT findings provide supportive observations but do not quantify the quality-of-life benefit for all 109 participants.
How could the MINT findings influence Poteligeo’s European commercial positioning?
For Kyowa Kirin, the significance of MINT lies primarily in strengthening the evidence available for an already commercialized oncology medicine. Poteligeo is a humanized monoclonal antibody targeting CC chemokine receptor 4, or CCR4, which is expressed on malignant T cells in mycosis fungoides and Sézary syndrome. Binding to CCR4 helps recruit immune effector mechanisms that destroy susceptible cells.
The medicine received European marketing authorization in November 2018 for adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. Its United States indication applies to adults with relapsed or refractory disease after at least one prior systemic treatment. The latest MINT results do not change these indications or establish a new regulatory authorization.
Instead, observational evidence may help inform discussions about treatment sequencing, patient characteristics and outcomes in routine clinical practice. Specialist centres frequently manage patients with differing disease manifestations, treatment histories and degrees of blood involvement. Additional evidence in such populations may be useful when clinicians assess available treatment strategies within the approved indication.
The commercial implications are nevertheless indirect. Stronger real-world evidence can support physician education, health technology assessment discussions and confidence in an established product, but it does not guarantee higher reimbursement, greater prescribing or increased market share. The observational data also cannot substantiate new superiority claims that were not demonstrated in controlled comparative trials.
Kyowa Kirin has identified Poteligeo as an important global specialty pharmaceutical product and reported continued commercial growth during 2026. The company has emphasized evidence-based communication and efforts to identify appropriate patients in North America and Europe. MINT aligns with that strategy by adding data from German clinical practice rather than expanding the product into an entirely new therapeutic market.
The study’s findings are therefore more appropriately considered an incremental commercial evidence milestone than a discrete earnings-changing regulatory catalyst. No additional sales commitments, new reimbursement decisions or material financial guidance revisions were announced with the final results. The longer-term contribution will depend on whether physicians and healthcare systems find the evidence useful in managing eligible patients.
What further evidence could clarify mogamulizumab’s role in individualized lymphoma treatment?
The final MINT analysis offers useful descriptive information about treatment outcomes across a heterogeneous German cutaneous T-cell lymphoma population. Its principal strengths include multicentre participation, an extended observation period and the inclusion of patients receiving different combinations of care. These characteristics make the findings relevant to routine clinical practice, where treatment decisions are rarely identical across every patient.
However, several limitations remain. The non-interventional design prevents causal comparisons between treatment strategies, while concurrent antineoplastic therapies complicate attribution of response. Small subgroup populations and incomplete quality-of-life follow-up also limit the precision of some clinically interesting findings.
The treatment-associated rash observations present another area where additional evidence could be useful. Understanding whether the relationship between rash and response persists after accounting for treatment duration, disease characteristics and other confounding factors could help clarify its clinical significance. Until then, rash should remain an adverse event requiring appropriate evaluation rather than being treated as an established indicator of therapeutic success.
Future real-world investigations may also help explain how outcomes differ according to blood involvement, disease stage, previous systemic treatments and the use of accompanying therapies. Prospective collection of these data, alongside standardized response assessments and patient-reported outcomes, would improve the interpretability of routine-care evidence. Such research could complement rather than replace the randomized trial data supporting mogamulizumab’s authorization.
The final MINT results reinforce that Poteligeo remains an active treatment option for adults with previously treated mycosis fungoides and Sézary syndrome, with meaningful responses observed across a range of clinical settings. At the same time, the severe adverse-event burden, treatment discontinuations and observational design prevent the headline response rate from being interpreted as evidence of superior efficacy or universal tolerability. For Kyowa Kirin, the next opportunity lies in using these findings to improve understanding of which eligible patients are most likely to experience sustained clinical benefit while ensuring that treatment decisions remain grounded in the medicine’s established safety profile and approved indication.
